Other Diseases

Epic Sciences garners USD 52 Million for blood tests in cancer patients Epic Sciences received USD 52 million to progress its suite of liquid biopsies that utilizes computer vision and machine learning to find circulating tumour cells while characterizing the immune response of the body at the same time. The Cancer blood test company also ruminates to utilize the new funds to club its tests with electronic health records and big data analytics to begin patterns in cancer cell evolution, drug selection and clinical outcomes. Tvardi Therapeutics gets financing for STAT3-driven diseases candidate TTI-101 program Tvardi Therapeutics has apprised regarding the completion ...